complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated. Society and culture It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. The drug's U.S. patent will expire in 2020. In May 2012, the US District Court of Delaware passed an order in favor of OSI Pharmaceutical LLC against Mylan Pharmaceuticals upholding the validity of the patent for Erlotinib. In India, generic pharmaceutical firm Cipla is battling with Roche against the Indian patent for this drug. References External links Amines Astellas Pharma Ethers Hoffmann-La Roche brands Genentech brands Phenol ethers Phenyl compounds Alkyne derivatives Quinazolines Receptor tyrosine kinase inhibitors World Health Organization essential medicines Wikipedia medicine articles ready to translate Orphan drugs